Christopher Hite is recorded as Chairman at Royalty Pharma plc (RPRX) and Board Member at Vera Therapeutics, Inc. (VERA) since January 1, 2026. The newest filing on record that lists Christopher Hite as Chairman at Royalty Pharma plc (RPRX) is dated April 10, 2026. The newest filing on record that lists Christopher Hite as Board Member at Vera Therapeutics, Inc. (VERA) is dated April 9, 2026. Vera Therapeutics, Inc. reported in an 8-K filed March 9, 2026 that Christopher Hite was appointed Class III Director, effective March 5, 2026. The proxy statement of Royalty Pharma plc reports total compensation of $1,323,000 for Christopher Hite in fiscal 2025, including a base salary of $1,323,000. Disclosed compensation is on record for 3 fiscal years. Christopher Hite has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Royalty Pharma plc on June 9, 2026. Royalty Pharma plc is classified in the Biotechnology industry within the Healthcare sector. Vera Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Royalty Pharma plc includes Pablo Legorreta (CEO), Vlad Coric (CEO and Board Member), David Hodgson (Chairman) and 7 others.
“On March 5, 2026, the board of directors (the "Board") of Vera Therapeutics, Inc. (the "Company") appointed Christopher Hite to the Board, effective immediately.”
Vera Therapeutics, Inc. Form 8-K, filed March 9, 2026
· Read the filing
Christopher Hite on recent calls
“Well, first of all, thank you very much for having us here. We're really delighted to be here at the Goldman Conference and great investor meetings today, and so thank you very much.”
“I'm genuinely excited about the new capabilities we're building and the opportunity to forge even stronger, more meaningful relationships across the biopharma ecosystem.”
“It's my pleasure to provide an update on our development stage pipeline. As a reminder, at our investor day, we highlighted that our pipeline is expected to generate over $36 billion in cumulative peak sales, which translates to over $2 billion in peak royalties to royalty pharma.”
“I want to give a brief update on our transaction pipeline and the tremendous opportunity set ahead of us. Slide 11 shows our transaction funnel. We're busy in 2024 reviewing more than 440 potential royalty transactions.”
“I want to expand on the frexalimab transaction and highlight the broader potential of our growing development-stage pipeline, which we think is underappreciated by the market.”
